Enanta Pharmaceuticals (ENTA) shares rallied 7.2% in the last trading session to close at $6.28. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 37.1% loss over the past four weeks.
The company’s lead candidate, zelicapavir, an oral, N-protein inhibitor, is being evaluated in two ongoing mid-stage studies to treat pediatric and adult patients with respiratory syncytial virus infection. The company also has a developmental portfolio of small-molecule drugs for viral infections. The growing optimism regarding the development of zelicapavir and other pipeline candidates might have driven the share price rally.
This biotechnology company is expected to post quarterly loss of $1.15 per share in its upcoming report, which represents a year-over-year change of +27.2%. Revenues are expected to be $17.51 million, down 2.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Enanta Pharmaceuticals, the consensus EPS estimate for the quarter has been revised 7.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ENTA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Enanta Pharmaceuticals is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Neurocrine Biosciences (NBIX), finished the last trading session 0.3% higher at $135.42. NBIX has returned 8% over the past month.
For Neurocrine
Zacks Naming Top 10 Stocks for 2025
Want to be tipped off early to our 10 top picks for the entirety of 2025?
History suggests their performance could be sensational.
From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.
Be First to New Top 10 Stocks >>Enanta Pharmaceuticals, Inc. (ENTA) : Free Stock Analysis Report
Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
